Kulkarni Samarth
CIK 0001682019 Name as filed on the most recent filing
Filed as Kulkarni Samarth (47)
107 transaction lines · from 47 filings · filed 2017-04-21 to 2026-03-24 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
107 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-23 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 10,020 disposed | 46.78 | 468,735.60 | Form 4, filing 0001193125-26-122272 | |
| 2026-03-16 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 10,349 disposed | 48.26 | 499,442.74 | Form 4, filing 0001193125-26-111278 | |
| 2026-03-11 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 9,798 disposed | 52.80 | 517,334.40 | Form 4, filing 0001193125-26-104480 | |
| 2026-02-19 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 6,967 disposed | 52.58 | 366,324.86 | Form 4, filing 0001193125-26-061712 | |
| 2026-01-22 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 60,000 disposed | 60.23 | 3,613,800.00 | Form 4, filing 0001193125-26-019733 | |
| 2026-01-20 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 21,433 disposed | 51.61 | 1,106,157.13 | Form 4, filing 0001193125-26-019733 | |
| 2026-01-20 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 8,567 disposed | 52.10 | 446,340.70 | Form 4, filing 0001193125-26-019733 | |
| 2025-10-17 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 50,895 disposed | 67.91 | 3,456,279.45 | Form 4, filing 0001193125-25-243819 | |
| 2025-10-14 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 4,242 disposed | 66.60 | 282,517.20 | Form 4, filing 0001193125-25-240438 | |
| 2025-08-18 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 13,081 disposed | 58.15 | 760,660.15 | Form 4, filing 0001682019-25-000003 | |
| 2025-03-21 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 10,031 disposed | 41.23 | 413,578.13 | Form 4, filing 0000950170-25-043975 | |
| 2025-03-12 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 4,462 disposed | 43.32 | 193,293.84 | Form 4, filing 0000950170-25-038216 | |
| 2025-03-11 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 9,973 disposed | 42.42 | 423,054.66 | Form 4, filing 0000950170-25-038216 | |
| 2025-02-19 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 6,928 disposed | 52.80 | 365,798.40 | Form 4, filing 0000950170-25-023385 | |
| 2025-02-19 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 18,360 disposed | 55.20 | 1,013,563.80 | Form 4, filing 0000950170-25-025000 | |
| 2025-02-18 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 11,640 disposed | 55.05 | 640,782.00 | Form 4, filing 0000950170-25-023385 | |
| 2024-12-02 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 15,000 disposed | 55.10 | 826,564.50 | Form 4, filing 0000950170-24-133373 | |
| 2024-11-11 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 23,121 disposed | 55.43 | 1,281,597.03 | Form 4, filing 0000950170-24-126521 | |
| 2024-11-11 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 6,879 disposed | 56.27 | 387,081.33 | Form 4, filing 0000950170-24-126521 | |
| 2024-10-14 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 4,293 disposed | 46.28 | 198,680.04 | Form 4, filing 0000950170-24-114786 | |
| 2024-04-15 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 18,378 disposed | 59.88 | 1,100,509.56 | Form 4, filing 0000950170-24-045196 | |
| 2024-04-15 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 1,204 disposed | 60.40 | 72,721.96 | Form 4, filing 0000950170-24-045196 | |
| 2024-03-15 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 10,613 disposed | 71.97 | 763,810.18 | Form 4, filing 0000950170-24-032989 | |
| 2024-03-15 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 9,387 disposed | 73.06 | 685,817.97 | Form 4, filing 0000950170-24-032989 | |
| 2024-03-12 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 4,583 disposed | 74.44 | 341,158.52 | Form 4, filing 0000950170-24-030189 | |
| 2024-03-11 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 9,802 disposed | 78.26 | 767,104.52 | Form 4, filing 0000950170-24-030189 | |
| 2024-02-20 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 6,370 disposed | 79.67 | 507,497.90 | Form 4, filing 0000950170-24-018174 | |
| 2024-02-15 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 12,949 disposed | 79.94 | 1,035,089.97 | Form 4, filing 0000950170-24-016574 | |
| 2024-02-15 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 5,951 disposed | 81.04 | 482,256.54 | Form 4, filing 0000950170-24-016574 | |
| 2024-02-15 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 1,100 disposed | 81.66 | 89,830.95 | Form 4, filing 0000950170-24-016574 | |
| 2024-01-29 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 49,300 disposed | 60.50 | 2,982,802.83 | Form 4, filing 0000950170-24-009505 | |
| 2024-01-29 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 700 disposed | 61.10 | 42,769.86 | Form 4, filing 0000950170-24-009505 | |
| 2024-01-16 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 20,000 disposed | 62.50 | 1,250,058.00 | Form 4, filing 0000950170-24-005492 | |
| 2023-05-30 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 9,300 disposed | 65.63 | 610,359.00 | Form 4, filing 0001209191-23-033394 | |
| 2023-05-30 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 7,301 disposed | 63.61 | 464,452.38 | Form 4, filing 0001209191-23-033394 | |
| 2023-05-30 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 5,999 disposed | 64.46 | 386,681.74 | Form 4, filing 0001209191-23-033394 | |
| 2023-05-30 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 2,400 disposed | 66.83 | 160,401.12 | Form 4, filing 0001209191-23-033394 | |
| 2023-04-25 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 20,607 disposed | 50.50 | 1,040,616.41 | Form 4, filing 0001209191-23-025901 | |
| 2023-04-25 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 4,393 disposed | 51.45 | 226,021.17 | Form 4, filing 0001209191-23-025901 | |
| 2023-03-29 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 19,719 disposed | 44.37 | 874,997.10 | Form 4, filing 0001209191-23-021911 | |
| 2023-03-29 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 5,281 disposed | 44.78 | 236,506.42 | Form 4, filing 0001209191-23-021911 | |
| 2023-02-27 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 13,720 disposed | 48.57 | 666,414.70 | Form 4, filing 0001209191-23-014273 | |
| 2023-02-27 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 10,180 disposed | 47.71 | 485,710.20 | Form 4, filing 0001209191-23-014273 | |
| 2023-02-27 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 1,100 disposed | 49.20 | 54,118.46 | Form 4, filing 0001209191-23-014273 | |
| 2023-01-27 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 23,200 disposed | 51.54 | 1,195,711.76 | Form 4, filing 0001209191-23-005769 | |
| 2023-01-27 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 1,800 disposed | 50.60 | 91,085.76 | Form 4, filing 0001209191-23-005769 | |
| 2022-12-28 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 20,366 disposed | 40.81 | 831,189.41 | Form 4, filing 0001209191-22-063026 | |
| 2022-12-28 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 4,634 disposed | 41.45 | 192,100.62 | Form 4, filing 0001209191-22-063026 | |
| 2022-11-28 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 17,118 disposed | 53.58 | 917,245.78 | Form 4, filing 0001209191-22-059060 | |
| 2022-11-28 |
Crispr Therapeutics AG CRSP |
S, Open-market sale | 5,572 disposed | 54.85 | 305,598.01 | Form 4, filing 0001209191-22-059060 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 0
- Open-market sale 107
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Kulkarni Samarth, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001682019
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6